Individualized Dosing and Administration of CAMZYOS

CAMZYOS (mavacamten) is initiated at a recommended starting dose of 5 mg orally once daily, regardless of food intake. Dose adjustments (2.5 mg, 5 mg, 10 mg, or 15 mg once daily) are made according to clinical response and echocardiographic assessment, particularly left ventricular ejection fraction (LVEF) and Valsalva LVOT gradient. The maximum recommended dose is 15 mg daily. Initiation is not recommended in patients with LVEF <55%, and treatment must be interrupted if LVEF drops below 50% or if clinical status worsens. Dosing in pediatric patients or those with severe hepatic impairment is not specified in the description.